NeuroSTAT – for treatment of traumatic brain injury
Traumatic brain injury (TBI) is caused by external force to the head resulting in immediate damage to nerve cells. The damage continues to worsen for several days after the acute trauma.
The aim for NeuroSTAT, targeting the mitochondria, is to counteract the emergence of neurological and functional secondary brain damage after a traumatic injury, and thereby establish a therapy that will lead to increased survival, improved quality of life and preserved neurological function.
Project status: candidate drug in clinical Phase 2
NeuroSTAT has shown favorable properties in a Phase Ib/IIa clinical study and in advanced experimental TBI models at the University of Pennsylvania (Penn). NeuroSTAT has orphan drug designation in Europe and the US as well as an IND approval and Fast Track designation for clinical development in the US.
Abliva continues discussions with the TRACK-TBI network regarding a potential collaboration within the scope of the Precision Medicine project for a Phase 2 study of traumatic brain injury with NeuroSTAT. TRACK-TBI has updated its timelines, hence the study, if authorized by US Department of Defense (DOD), would commence in 2023 at the earliest, contingent upon DOD’s approval of earlier steps of the project.
With a potential agreement with TRACK-TBI as a partner, the company will review possible options that may enable developing the NeuroSTAT program further.
Primary mitochondrial disorders
Abliva is interested in partnering its innovative primary mitochondrial disorders portfolio to advance these programs as effectively as possible. The company can consider different partnering models, depending on what is optimal for our programs and partners.